Multiple Sequential Steps Involved in the Binding of Inhibitors to Cytochrome P450 3A4*

Cytochrome P450 (P450) 3A4 is an extensively studied human enzyme involved in the metabolism of >50% of drugs. The mechanism of the observed homotropic and heterotropic cooperativity in P450 3A4-catalyzed oxidations is not well understood, and together with the cooperative behavior, a detailed understanding of interaction of drug inhibitors with P450 3A4 is important in predicting clinical drug-drug interactions. The interactions of P450 3A4 with several structurally diverse inhibitors were investigated using both kinetic and thermodynamic approaches to resolve the steps involved in binding of these ligands. The results of pre-steady-state absorbance and fluorescence experiments demonstrate that inhibitor binding is clearly a multistep process, even more complex than the binding of substrates. Based on spectrophotometric equilibrium binding titrations as well as isothermal titration calorimetry experiments, the stoichiometry of binding appears to be 1:1 in the concentration ranges studied. Using a sequential-mixing stopped-flow approach, we were also able to show that the observed multiphasic binding kinetics is the result of sequential events as opposed to the existence of multiple enzyme populations in dynamic equilibrium that interact with ligands at different rates. We propose a three-step minimal model for inhibitor binding, developed with kinetic simulations, consistent with our previously reported model for the binding of substrates, although it is possible that even more steps are involved.

[1]  P. Gannett,et al.  Heteroactivator effects on the coupling and spin state equilibrium of CYP2C9. , 2006, Archives of biochemistry and biophysics.

[2]  A. Fersht Structure and mechanism in protein science , 1998 .

[3]  Jay R. Knutson,et al.  Simultaneous analysis of multiple fluorescence decay curves: A global approach , 1983 .

[4]  A. P. Koley,et al.  Cytochrome P450 conformation and substrate interactions as probed by CO binding kinetics. , 1996, Biochimie.

[5]  M. Cameron,et al.  Cooperative binding of midazolam with testosterone and alpha-naphthoflavone within the CYP3A4 active site: a NMR T1 paramagnetic relaxation study. , 2005, Biochemistry.

[6]  W. Atkins,et al.  Time-resolved fluorescence studies of heterotropic ligand binding to cytochrome P450 3A4. , 2006, Biochemistry.

[7]  P. Kuzmič,et al.  Program DYNAFIT for the analysis of enzyme kinetic data: application to HIV proteinase. , 1996, Analytical biochemistry.

[8]  Nina Isoherranen,et al.  Surface plasmon resonance analysis of antifungal azoles binding to CYP3A4 with kinetic resolution of multiple binding orientations. , 2006, Biochemistry.

[9]  F. Guengerich,et al.  Cytochrome P-450 3A4: regulation and role in drug metabolism. , 1999, Annual review of pharmacology and toxicology.

[10]  S. D. Turner,et al.  Substrate-dependent modulation of CYP3A4 catalytic activity: analysis of 27 test compounds with four fluorometric substrates. , 2000, Drug metabolism and disposition: the biological fate of chemicals.

[11]  J. Halpert,et al.  Resolution of multiple substrate binding sites in cytochrome P450 3A4: the stoichiometry of the enzyme-substrate complexes probed by FRET and Job's titration. , 2006, Biochemistry.

[12]  W. Atkins Current views on the fundamental mechanisms of cytochrome P450 allosterism , 2006, Expert opinion on drug metabolism & toxicology.

[13]  A. Kappas,et al.  7,8-Benzoflavone stimulates the metabolic activation of aflatoxin B1 to mutagens by human liver. , 1978, Biochemical and biophysical research communications.

[14]  S. Sligar,et al.  Kinetics of dithionite-dependent reduction of cytochrome P450 3A4: heterogeneity of the enzyme caused by its oligomerization. , 2005, Biochemistry.

[15]  I. B. C. Matheson,et al.  A critical comparison of least absolute deviation fitting (robust) and least squares fitting: The importance of error distributions , 1990, Comput. Chem..

[16]  T. Sjögren,et al.  Structural basis for ligand promiscuity in cytochrome P450 3A4 , 2006, Proceedings of the National Academy of Sciences.

[17]  R. Estabrook,et al.  Spectral studies of drug interaction with hepatic microsomal cytochrome. , 1967, Molecular pharmacology.

[18]  M. Relling,et al.  Pharmacogenomics: translating functional genomics into rational therapeutics. , 1999, Science.

[19]  A. P. Koley,et al.  Differential Mechanisms of Cytochrome P450 Inhibition and Activation by α-Naphthoflavone* , 1997, The Journal of Biological Chemistry.

[20]  J. Ladbury Application of isothermal titration calorimetry in the biological sciences: things are heating up! , 2004, BioTechniques.

[21]  H. Yamazaki,et al.  Roles of NADPH-P450 reductase and apo- and holo-cytochrome b5 on xenobiotic oxidations catalyzed by 12 recombinant human cytochrome P450s expressed in membranes of Escherichia coli. , 2002, Protein expression and purification.

[22]  Z. Sauna,et al.  Exploiting Reaction Intermediates of the ATPase Reaction to Elucidate the Mechanism of Transport by P-glycoprotein (ABCB1)* , 2006, Journal of Biological Chemistry.

[23]  F. Guengerich,et al.  Expression of modified human cytochrome P450 3A4 in Escherichia coli and purification and reconstitution of the enzyme. , 1993, Archives of biochemistry and biophysics.

[24]  F. Guengerich,et al.  Kinetic Analysis of Oxidation of Coumarins by Human Cytochrome P450 2A6* , 2005, Journal of Biological Chemistry.

[25]  D. Clarke,et al.  Transmembrane segment 1 of human P-glycoprotein contributes to the drug-binding pocket. , 2006, The Biochemical journal.

[26]  A. Y. Lu,et al.  Allosteric behavior in cytochrome p450-dependent in vitro drug-drug interactions: a prospective based on conformational dynamics. , 2001, Chemical research in toxicology.

[27]  Aleksandra Galetin,et al.  Modelling atypical CYP3A4 kinetics: principles and pragmatism. , 2005, Archives of biochemistry and biophysics.

[28]  D. Greenblatt,et al.  Five Distinct Human Cytochromes Mediate Amitriptyline N‐Demethylation In Vitro: Dominance of CYP 2C19 and 3A4 , 1998, Journal of clinical pharmacology.

[29]  W. Atkins,et al.  The thermodynamic landscape of testosterone binding to cytochrome P450 3A4: ligand binding and spin state equilibria. , 2005, Biochemistry.

[30]  W. Atkins,et al.  Non-Michaelis-Menten kinetics in cytochrome P450-catalyzed reactions. , 2005, Annual review of pharmacology and toxicology.

[31]  Eric F. Johnson,et al.  The Structure of Human Microsomal Cytochrome P450 3A4 Determined by X-ray Crystallography to 2.05-Å Resolution* , 2004, Journal of Biological Chemistry.

[32]  Ortiz de Montellano,et al.  Cytochrome P-450: Structure, Mechanism, and Biochemistry , 1986 .

[33]  F. Guengerich,et al.  Rate-limiting steps in oxidations catalyzed by rabbit cytochrome P450 1A2. , 2004, Biochemistry.

[34]  I. B. C. Matheson Robust estimation of parameters: A simple modification to all non-linear fitting algorithms to convert from minimizing the sum of squares of deviations to minimizing the sum of the absolute deviations , 1989, Comput. Chem..

[35]  L. Wienkers,et al.  Pyrene.pyrene complexes at the active site of cytochrome P450 3A4: evidence for a multiple substrate binding site. , 2002, Journal of the American Chemical Society.

[36]  T. Shimada,et al.  Evidence for cytochrome P-450NF, the nifedipine oxidase, being the principal enzyme involved in the bioactivation of aflatoxins in human liver. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[37]  J. Houston,et al.  Multisite kinetic models for CYP3A4: simultaneous activation and inhibition of diazepam and testosterone metabolism. , 2001, Drug metabolism and disposition: the biological fate of chemicals.

[38]  G. Miller,et al.  Binding and oxidation of alkyl 4-nitrophenyl ethers by rabbit cytochrome P450 1A2: evidence for two binding sites. , 2001, Biochemistry.

[39]  W. Pryor Cytochrome P450: Structure, mechanism, and biochemistry , 1996 .

[40]  J. Halpert,et al.  Analysis of homotropic and heterotropic cooperativity of diazepam oxidation by CYP3A4 using site-directed mutagenesis and kinetic modeling. , 2003, Archives of biochemistry and biophysics.

[41]  K. Korzekwa,et al.  Activation of CYP3A4: evidence for the simultaneous binding of two substrates in a cytochrome P450 active site. , 1994, Biochemistry.

[42]  T. Tracy,et al.  Dapsone activation of CYP2C9-mediated metabolism: evidence for activation of multiple substrates and a two-site model. , 2001, Drug metabolism and disposition: the biological fate of chemicals.

[43]  H. Yamazaki,et al.  Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. , 1994, The Journal of pharmacology and experimental therapeutics.

[44]  F. Guengerich,et al.  A malleable catalyst dominates the metabolism of drugs , 2006, Proceedings of the National Academy of Sciences.

[45]  Sean Ekins,et al.  In vitro and pharmacophore insights into CYP3A enzymes. , 2003, Trends in pharmacological sciences.

[46]  N. Oppenheimer,et al.  Structure and mechanism , 1989 .

[47]  F Peter Guengerich,et al.  Kinetics and Thermodynamics of Ligand Binding by Cytochrome P450 3A4* , 2006, Journal of Biological Chemistry.

[48]  D. Clarke,et al.  Recent Progress in Understanding the Mechanism of P-Glycoprotein-mediated Drug Efflux , 2005, The Journal of Membrane Biology.

[49]  T. Baillie,et al.  A Kinetic Model for the Metabolic Interaction of Two Substrates at the Active Site of Cytochrome P450 3A4* , 2001, Journal of Biological Chemistry.

[50]  M. Maeder,et al.  Nonlinear least-squares fitting of multivariate absorption data , 1990 .

[51]  D. Clarke,et al.  Substrate-induced Conformational Changes in the Transmembrane Segments of Human P-glycoprotein , 2003, The Journal of Biological Chemistry.

[52]  A. P. Koley,et al.  Drug-drug interactions: effect of quinidine on nifedipine binding to human cytochrome P450 3A4. , 1997, Biochemical pharmacology.

[53]  A. Rettie,et al.  Differential activation of CYP2C9 variants by dapsone. , 2004, Biochemical pharmacology.

[54]  Jose Cosme,et al.  Crystal Structures of Human Cytochrome P450 3A4 Bound to Metyrapone and Progesterone , 2004, Science.

[55]  S. Sligar,et al.  Homotropic cooperativity of monomeric cytochrome P450 3A4 in a nanoscale native bilayer environment. , 2004, Archives of biochemistry and biophysics.

[56]  B. Griffin,et al.  Camphor binding by Pseudomonas putida cytochrome P-450. Kinetics and thermodynamics of the reaction. , 1972, Biochemistry.

[57]  M. Shou Kinetic analysis for multiple substrate interaction at the active site of cytochrome P450. , 2002, Methods in enzymology.

[58]  D. Dunbar,et al.  Characterization of human small intestinal cytochromes P-450. , 1999, Drug metabolism and disposition: the biological fate of chemicals.

[59]  I. Matheson The Method of Successive Integration: a General Technique for Recasting Kinetic Equations in a Readily Soluble Form Which Is Linear in the Coefficients and Sufficiently Rapid for Real Time Instrumental Use. , 1987 .

[60]  J. Halpert,et al.  Structures of cytochrome P450 3A4. , 2005, Trends in biochemical sciences.

[61]  Tony F. Chan,et al.  An Improved Algorithm for Computing the Singular Value Decomposition , 1982, TOMS.

[62]  D. Clarke,et al.  Do drug substrates enter the common drug-binding pocket of P-glycoprotein through "gates"? , 2005, Biochemical and biophysical research communications.

[63]  Fumiyoshi Yamashita,et al.  QSAR Analysis of the Inhibition of Recombinant CYP 3A4 Activity by Structurally Diverse Compounds Using a Genetic Algorithm-Combined Partial Least Squares Method , 2003, Pharmaceutical Research.

[64]  H. Yamazaki,et al.  Lack of Electron Transfer from Cytochrome b5 in Stimulation of Catalytic Activities of Cytochrome P450 3A4 , 1996, The Journal of Biological Chemistry.

[65]  G. Miller,et al.  Elucidation of distinct ligand binding sites for cytochrome P450 3A4. , 2000, Biochemistry.

[66]  S. Ekins,et al.  Examination of purported probes of human CYP2B6. , 1997, Pharmacogenetics.

[67]  A. Conney,et al.  Activation of monooxygenases in human liver by 7,8‐benzoflavone , 1977, Clinical pharmacology and therapeutics.